Audentes accelerated approval in 2020 a possibility, says H.C. Wainwright
Potential accelerated approval for Audentes Therapeutics's AT132 during 2020 is "viable, highly desirable, and imminently pursuable," H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "AT132 Accelerated Approval During 2020 Is Well Within the Realm of Possibilities." While management is not guiding to it, the data thus far supports the underlying premise for accelerated approval, says Chattopadhyay. He believes the Q3 of 2019 update from additional patients is likely to establish AT132 "not only as the first but best in class gene therapy" for X-linked myotubular myopathy. The analyst keeps a Buy rating on Audentes Therapeutics with a $33 price target.